Patients with neovascular age-related macular degeneration (nAMD) who have been stable on 3-month anti-VEGF injections for at least 2 years can often be safely extended to 4-month intervals without loss of vision or disease control, according to a study.
The study included 88 eyes (mean age 83.4 years; 64.8% female) treated with aflibercept (n = 56) or ranibizumab (n = 32). Disease recurrence, which was defined as new or increased fluid, hemorrhage, or lesion growth on optical coherence tomography (OCT), occurred in 10.2% (9/88) of cases. Most recurrences appeared within the first year of extension.
The researchers noted that visual acuity remained stable despite recurrence, with mean vision before and after recurrence unchanged (20/30). All but 1 eye regained baseline acuity within 1 Snellen line after resuming 3- or 4-month injection intervals.
Reference
Basilious A, Yuan AT, Sheidow TG. Outcomes of 16-week extension of anti-VEGF therapy in neovascular age-related macular degeneration. Can J Ophthalmol. 2025;S0008-4182(25)00443-0. doi: 10.1016/j.jcjo.2025.10.002. Epub ahead of print. PMID: 41183785.
Related Content
